

ARIC CASE AND COMPARISON STUDY GROUPS

Introduction

ARIC has implemented a series of case-cohort studies and some case-control studies since the mid-90s. They varied by the baseline population being from a particular ARIC exam (1-4), and even within exam there has sometimes been more than one cohort random sample. There have also been multiple outcome variables of interest, and differing lengths of follow-up. And, of course, there have been many exposure variables of interest. Below is a table summarizing these various study designs, and there follows a table listing the exposure variables of interest for these studies. We do not include here data from ancillary studies. Historically ARIC has tracked these different sub-studies in tables with the imaginative names of Table 2, Table 3, and Table 4, and it is convenient to not entirely abandon this historical tracking system, so the tables below reference those Tables 2-4. There follow detailed descriptions of the study designs related to each Table 2-4, along with suggestions for analysis of data from these designs.

ARIC Case Cohort Studies

| Cohort Random Sample/Control Group** | | | Case Groups | | |
|--------------------------------------|-----------------|---------|--------------------------------|-----------------------------|--------|
| Name | Source | Size* | Name | Source | Size* |
| Table 2 Small | Visit 1 | 556 | Incident CHD | Visit 1-31Dec91 | 267 |
| | | | Incident CHD | Visit 1-31Dec93 | 471 |
| Table 2 Large | Visit 1 | 989 | Incident CHD | Visit 1-31Dec91 | 267 |
| | | | Incident CHD | Visit 1-31Dec93 | 471 |
| Table 2 Large | Visit 1 | 989 | Prevalent PAD | Visit 1 | 237 |
| Table 3 | Visit 2 | 486 | Incident CHD | Visit 2-31Dec95 | 406 |
| Periodontal | Visit 4 | 200 | Periodontal | Visit 4 | 207 |
| MRI | Visit 3 | 267 | MRI | Visit 3 | 237 |
| Diabetes | Visit 1 | 681 | Incident Diabetes | Visit 1-Visit 4 | 581 |
| Stroke | Visit 1 | 989 | Incident Stroke | Visit 1-31Dec96 | 231 |
| Table 4 | Visit 2 | 936 | Incident CHD | Visit 2-31Dec98 | 775 |
| Table 4 | Visit 2 | 936 | Incident Stroke | Visit 2-31Dec98 | 248 |
| Table 4 | Visit 1 | 1062 | Incident Stroke DNA studies | Visit 1-31Dec00 | 356 |
| Table 4 | Visit 1 | 1062 | Incident CHD DNA studies | Visit 1-31Dec00 | 1081 |
| Visit 3/Visit 4 PAD** | Visit 3/Visit 4 | 198/354 | Visit 3/Visit 4 PAD | Visit 3/Visit 4- 31Dec00 | 99/177 |

*varies somewhat by analyte

**uses control group instead of CRS

Table 2 Version**ARIC Incident CHD Case-Cohort Studies**

Cases Through 31 Dec 1991 Follow-up from Visit 1

N=267 for incident CHD; number may vary by analyte

Cohort Random Sample (CRS) identified in UC250921 by INSAM1=1 (n=989) or INSAM2=1(n=556)

| ANALYTES | Dataset containing Analyte | Large (1) or Small (2) CRS | MS Proposal |
|-------------------------------|-----------------------------------|-----------------------------------|--------------------|
| B(12) vitamin | VTBA01 | 2 | 389 |
| B(6) vitamin | VTBA01 | 2 | 389 |
| CBS insertion genotype | HCYA01 | 2 | 389 |
| CBS (G919A) genotype | HCYA01 | 2 | 389 |
| CBS (T833C) genotype | HCYA01 | 2 | 389 |
| Chlamydia pneumoniae Antibody | CLMB01 | 2 | 439 |
| CMV | CMVA01 | 2 | 375 |
| Folate | VTBA01 | 2 | 389 |
| Herpes Simplex I antibody | CMVA01 | 2 | 375 |
| Helicobacter Pylori Antibody | HPYA01 | 2 | 453 |
| Hemochromatosis genotype | HEMO01 | 2 | 599 |
| Homocysteine | HMEB01 | 2 | 389 |
| MTHFR (C677T) genotype | HCYA01 | 2 | 389 |
| Plasma fatty acids | FATA0 | 2 | 581 |

ARIC Incident CHD Case-Cohort Studies

Cases Through 31 Dec 1993 Follow-up from Visit 1

N=471 for incident CHD; number may vary by analyte

Cohort Random Sample (CRS) identified in UC250921 by INSAM1=1 (n=989) or INSAM2=1(n=556)

| ANALYTES | Dataset containing Analytes | Large (1) or Small (2) CRS | MS Proposal |
|---|------------------------------------|-----------------------------------|--------------------|
| Angiotensin II type 1 receptor (AT1R) | DNAT201 | 1 | 586 |
| ACE genotype | DNAT201 | 1 | |
| Adducin gene Gly 460 Trp | DNAT201 | 1 | 624 |
| Angiotensinogen -6 | DNAT201 | 1 | 586 |
| Angiotensinogen genotypeM235T | DNAT201 | 1 | 352 |
| ApoA-I | ALIP01 | 1 | |
| ApoC-III | ALIP01 | 1 | |
| Apo B signal peptide genotype | DNAT201 | 1 | 560 |
| Beta-3 adrenergic receptor Trp64 Arg mutation genotype | DNAT201 | 1 | 536 |
| B-thromboglobulin | BTGA01 | 1 | 597 |
| CETP | CEPT01 | 1 | |
| CETP genotype | DNAT201 | 1 | 560 |
| C-reactive protein | CRPA01 | 1 | 606 |
| D-dimer | DDMA01 | 1 | 648 |
| Endothelial nitric oxide Synthase polymorphism | DNAT201 | 1 | |
| E-selectin | ALIP01 | 1 | 350, 677 |
| E-selectin genotype | DNAT201 | 1 | 491 |
| F1.2 | F12A01 | 1 | 552, 648 |
| Factor V Leiden | FVLA01 | 2 | 740 |
| Factor XIII polymorphism | FX3A01 | 2 | 466, 844 |
| Fibrinogen G-455A genotype | G45A01 | 2 | 649, 844 |
| G protein b ₃ | DNAT201 | 1 | 624 |
| Glucagon receptor polymorphism | DNAT201 | 1 | |
| GSTM1, GSTT1 | DNAT201 | 1 | 601 |
| Hepatic lipase genotype | DNAT201 | 1 | 560 |
| ICAM-1 | ALIP01 | 1 | 350, 677 |
| Leptin | T2LIPIDP | 1 | 620, 677 |
| Lipoprotein lipase polymorphism LPL 447 truncation genotype | DNAT201 | 1 | 560 |
| Lp(a) Isoforms | ALIP01 | 1 | |
| L-selectin | T2LIPIDP | 1 | 677 |
| Monocyte Chemo-attractant Protein-1 (MCP-1) | MCP1P | 1 | 869 |

| ANALYTES | Dataset containing Analytes | Large (1) or Small (2) CRS | MS Proposal |
|--|------------------------------------|-----------------------------------|--------------------|
| P-selectin | T2LIPIDP | 1 | |
| PAI-1 | PAIA01 | 1 | 648 |
| PAI-1 g-type | PAIB01 | 2 | 648 |
| Paraoxonase genotype | DNAT201 | 1 | 560 |
| Plasminogen | PLG01 | 1 | |
| Platelet alpha-2 beta-1 receptor polymorphism (Sweetman) | A2B101 | 2 | 471-WD |
| Platelet glycoprotein Ib polymorphism (Lopez) | GPIB01 | 2 | 465 |
| Platelet glycoprotein IIIa polymorphism | GP3A01 | 2 | 436 |
| Prothrombin gene polymorphism (G20210A) | PR2A01 | 2 | 595-WD |
| Soluble thrombomodulin | THRM01 | 1 | 543 |
| Thrombomodulin Polymorphism (C/T Ala455Val) | T45A01 | 2 | 596 |
| Tpa | TPA01 | 1 | 648 |
| VCAM-1 | ALIP01 | 1 | 350 |

ARIC Visit 1 Peripheral Artery Disease (PAD) Case-Control Studies and Analytes

Cases at visit 1 (n=237)

Cohort Random Sample (CRS) identified in UC250921 by INSAM1=1 (n=989)

PAD is defined by ankle brachial index (<.9 males, <.85 females)

| ANALYTES | Dataset containing Analytes | MS Proposal |
|---|-----------------------------|-------------|
| Angiotensin II type 1 receptor (AT1R) | DNAT201 | 586 |
| Angiotensinogen -6 | DNAT201 | 586 |
| Angiotensinogen genotype M235T | DNAT201 | 352 |
| apo B signal peptide genotype | DNAT201 | 560 |
| ApoA-I | ALIP01 | |
| Beta-3 adrenergic receptor Trp64 Arg mutation genotype | DNAT201 | 536 |
| B-thromboglobulin | BTGA01 | 597 |
| CETP | CEPT01 | |
| CETP genotype | DNAT201 | 560,848 |
| C-reactive protein | CRPA01 | 606 |
| D-dimer | DDMA01 | 648 |
| Endothelial nitric oxide Synthase polymorphism | DNAT201 | |
| E-Selectin | ALIP01 | |
| E-selectin genotype | DNAT201 | 491 |
| F1.2 | F12A01 | 552, 648 |
| G protein b ₃ | DNAT201 | 624 |
| Glucagon receptor polymorphism | DNAT201 | |
| Hepatic lipase genotype | DNAT201 | 560 |
| ICAM-1 | ALIP01 | |
| Leptin | ALIP01 | 620, 677 |
| Lipoprotein lipase polymorphism LPL 447 truncation genotype LPL Asn291 Ser genotype | DNAT201 | 560 |
| Lp(a) isoforms | ALIP01 | |
| L-Selectin | ALIP01 | |
| Monocyte Chemo-attractant Protein-1 (MCP-1) | ALIP01 | 869 |
| PAI-1 | PAIA01 | 648 |
| PAI-1 g-type | PAIB01 | 648 |
| Paraoxonase genotype | DNAT201 | 560 |
| Plasminogen | PLG01 | |
| Soluble Thrombomodulin | THRM01 | |
| Tpa | TPA01 | 648 |

Table 3 Version

ARIC Incident CHD Case-Cohort Studies

Cases are post visit 2 through 31 Dec 1995 (n=406) and analytes are measured at visit 2 except for DNA
 Visit 2 Cohort Random Sample (CRS) (n=486) is a stratified by IMT, sex and age at visit 1 selected in UC3191
 Visit 1 CRS for DNA analysis is the same as the large Table 2 CRS at visit 1 (n=989)

Note: Most of the table 3 visit 2 CRS members were also in the table 2 visit 1 CRS

| Analyte | Dataset containing analyte | MS Proposal |
|---|----------------------------|-------------|
| Fibrinogen | HEM_V2C | 777 |
| Inflammatory CRP | HEM_V2C | 777 |
| Interleukin-6 | IL601 | |
| MMP-1 | TIMM01 | 870 |
| Thrombomodulin polymorphism Ala-455\Val | HEMTM455 | |
| TIMP-1 | TIMM01 | 870 |
| Von Willebrand Factor | HEM_V2C | 777 |

ARIC Periodontal Disease Case-Cohort Studies

Cases (n=207) and CRS (n=200) from visit 4 selected in UC3149

| Analyte | Dataset containing analyte | MS Proposal |
|----------------------------|----------------------------|-------------|
| CRP | HEM_V4P | 852 |
| D-dimer | HEM_V4P | 852 |
| Endothelial thrombomodulin | HEM_V4P | |
| Fibrinogen | HEM_V4P | 852 |
| PAI-1 | HEM_V4P | 852 |
| Plasminogen | HEM_V4P | 852 |
| TPA | HEM_V4P | 852 |
| VWF | HEM_V4P | 852 |

ARIC MRI Infarct Case-Control Studies
(at Forsyth County and Jackson field centers)
Cases (n=237) and Controls (n=267) selected in UC3066
Analytes from visit 3 except DNA

| Analyte | Dataset containing analyte | MS Proposal |
|---------------------------------|----------------------------|-------------|
| ACE I/D | DNAT301 | |
| Adducin | DNAT301 | 717 |
| Angioten A(6) | DNAT301 | |
| ANP | DNAT301 | |
| ApoB | DNAT301 | |
| ApoE | DNAT301 | 732 |
| CD36 | DNAT301 | |
| CRP | HEM_V3M | 847 |
| D-dimer | HEM_V3M | 847 |
| Endothelial thrombomodulin | HEM_V3M | 847 |
| eNOS | DNAT301 | |
| Fibrinogen | HEM_V3M | |
| G prot B3 | DNAT301 | 717 |
| ICAM | DNAT301 | |
| LPL genotype | DNAT301 | 732 |
| MMP3 | DNAT301 | |
| PAI-1 | HEM_V3M | 847 |
| Plasminogen | HEM_V3M | 847 |
| Platelet Btg | HEM_V3M | 847 |
| P-selectin | DNAT301 | |
| Thrombomodulin poly Ala-455\Val | HEM_V3M | 847 |
| TPA | HEM_V3M | 847 |
| VWF | HEM_V3M | 847 |

ARIC Ancillary Incident Diabetes Case-Cohort Studies

Cases were stratified random sample (n=581) of post visit 1 incident diabetes cases Stratifying by race after excluding cases who were also incident CHD or Stroke or in the table 2 CRS

| Analyte | Dataset containing analyte | MS Proposal |
|-----------|----------------------------|-------------|
| Anti-GAD | AGAD01 | |
| IL-6 | IL601 | 682, 853 |
| TNF-alpha | TNF01 | 682 |

ARIC Incident Ischemic Stroke Case-Cohort Studies

Incident Ischemic Stroke Cases through 31 December 1996 Follow-up from Visit 1
(n=231) selected in UC3165

Cohort Random Sample (CRS) (n=989) from table 2 Incident CHD studies

| Analyte | Dataset containing analyte | MS Proposal |
|---|----------------------------|-------------|
| ACE I/D | DNAT301 | 588 |
| Adducin | DNAT301 | 717 |
| ApoE | DNAT301 | 732 |
| ANP | DNAT301 | |
| Angioten A(6) | DNAT301 | 716 |
| CD36 | DNAT301 | |
| eNOS | DNAT301 | 717 |
| G prot B3 | DNAT301 | |
| ICAM | DNAT301 | 732 |
| LPL genotype | DNAT301 | 1014 |
| MMP3 | DNAT301 | |
| P-selectin | DNAT301 | |
| Thrombomodulin polymorphism Ala-455\Val | HEMTM455 | |

Table 4 Version

ARIC Incident CHD Case-Cohort Studies

Post Visit 2 Cases (n=775) through 31 Dec 1998

The Cohort Random Sample (CRS) (n=936) is from visit 2, stratified by race, sex and age at visit 1, selected in UC362301

Note: This visit 2 CRS is disjoint from the visit 2 CRS in table 3

| Analyte | Dataset containing analyte | MS Proposal |
|-------------------------|----------------------------|-------------|
| Alpha2-AP | T4_hemo_p | |
| Beta TG | Not started Yet | |
| CD40 Ligand | T4lipid1_p | 941 |
| D-Dimer | Not started Yet | |
| Factor II (Prothrombin) | T4_hemo_p | 777 |
| Factor IX | T4_hemo_p | 777 |
| Factor V | T4_hemo_p | 777 |
| Factor X | T4_hemo_p | 777 |
| Factor XI | T4_hemo_p | 777 |
| Factor XII | T4_hemo_p | 777 |
| Heparin Co-F2 | Heparin_p | 843 |
| HS CRP | T4lipid1_p | 889,1032 |
| ICAM-1 | T4lipid1_p | 941 |
| LpPLA2 | T4lipid1_p | 889 |
| Plasminogen | T4_hemo_p | |
| Protein Z | T4_hemo_p | 821 |
| Protein ZPI | Data not at CC | 821 |

ARIC Incident Ischemic Stroke Case-Cohort Studies

Post Visit 2 Cases (n=248) through 31 Dec 1998

The Cohort Random Sample (CRS) (n=936) is of visit 2, stratified by race, sex and age at visit 1 selected in UC362301

Note: This visit 2 CRS is disjoint from the visit 2 CRS in table 3

| Analyte | Dataset containing analyte | MS Proposal |
|-------------------------|----------------------------|-------------|
| Factor II (Prothrombin) | T4_hemo_p | 777 |
| Factor V | T4_hemo_p | 777 |
| Factor IX | T4_hemo_p | 777 |
| Factor X | T4_hemo_p | 777 |
| Factor XI | T4_hemo_p | 777 |
| Factor XII | T4_hemo_p | 777 |
| Plasminogen | T4_hemo_p | |
| Alpha2-AP | T4_hemo_p | |
| Heparin Co-F2 | Heparin_c | 843 |
| Protein Z | T4_hemo_p | 821 |
| Protein ZPI | Data not at CC | 821 |
| Soluble Thrombomodulin | Not started Yet | |
| D-Dimer | Not started Yet | |
| Beta TG | Not started Yet | |
| ICAM-1 | T4lipid1_p | 941 |
| LpPLA2 | T4lipid1_p | 940 |
| HS CRP | T4lipid1_p | 940 |
| CD40 Ligand | T4lipid1_p | 941 |

ARIC Incident Ischemic Stroke Case Cohort Studies of DNA

Post Visit 1 Cases (n=356) through 31 Dec 1998

Cohort Random Sample (CRS) is from visit 1, stratified by race, sex and age at visit 1 selected in UC362301

Note: This visit 1 CRS is disjoint from the visit 1 CRS in table 2, but contains the visit 2 CRS of table 4.

| Genotype | Genotype Dataset | MS Proposal |
|-------------------|------------------|-------------|
| CRP | T4dna_p | |
| IL-6 | T4dna_p | 967 |
| Lymphotoxin alpha | T4dna_p | 935 |
| MMP-9 | T4dna_p | 1014 |
| P-Selectin | T4dna_p | 1002 |
| Thrombospondin | T4dna_p | 935 |
| TNF-alpha | T4dna_p | |

ARIC Incident CHD Case Cohort Studies of DNA

Post Visit 2 Cases (n=1081) through 31 Dec 1998

Cohort Random Sample (CRS) is from visit 1, stratified by race, sex and age at visit 1 selected in UC362301

Note: This visit 1 CRS is disjoint from the visit 1 CRS in table 2, but contains the visit 2 CRS of table 4.

| Genotype | Genotype Dataset | MS Proposal |
|-------------------|------------------|-------------|
| CRP | T4dna_p | 1032 |
| IL-6 | T4dna_p | 967 |
| Lymphotoxin alpha | T4dna_p | 935,936 |
| MMP-9 | T4dna_p | 1014 |
| P-Selectin | T4dna_p | 1002 |
| Thrombospondin | T4dna_p | 935 |
| TNF-alpha | T4dna_p | |

Analytes for Case Control Studies

| Analyte Names | CRS/Control Group | CRS Source | Case Group and/or Source | Blood Source |
|-----------------------|--|--|--|--|
| ADAMTS-13 Ag | Visit3: CRS (N=148)/Visit4:CRS (N=234) | Visit3/Visit4 | PADv3 (N=148)/PADv4 (N=234) | Lipid Lab |
| Adip HMwt | a case cohort study of incident diabetes that includes a random sample of incident diabetes cases (n=581) and a random sample of the cohort (n=693). | Visit 1 | a case cohort study of incident diabetes that includes a random sample of incident diabetes cases (n=581) and a random sample of the cohort (n=693). | ARIC Visit 1 EDTA plasma samples stored at the lipid lab |
| Adip total | a case cohort study of incident diabetes that includes a random sample of incident diabetes cases (n=581) and a random sample of the cohort (n=693). | Visit 1 | a case cohort study of incident diabetes that includes a random sample of incident diabetes cases (n=581) and a random sample of the cohort (n=693). | ARIC Visit 1 EDTA plasma samples stored at the lipid lab |
| ADMA | a case cohort study of incident diabetes that includes a random sample of incident diabetes cases (n=581) and a random sample of the cohort (n=693). | Visit 1 | a case cohort study of incident diabetes that includes a random sample of incident diabetes cases (n=581) and a random sample of the cohort (n=693). | ARIC Visit 1 EDTA plasma samples stored at the lipid lab |
| albumin | N/A (all visit 4 participants with specimen) | N/A (all visit 4 participants with specimen) | N/A (all visit 4 participants with specimen) | Urine source -- University of Minnesota |
| Alpha Fetoprotein | | Visit 1/Visit 2/Visit 4 | | control samples came from the Minnesota inventory and the serum for the cases came from Baylor inventory |
| Alpha-2 Macroglobulin | | Visit 1/Visit 2/Visit 4 | | control samples came from the Minnesota inventory and the serum for the cases came from Baylor inventory |
| Alpha2-AP [4] | CRS (n=936) | Visit 2 | Incident CHD , Visit 2-31 December 98 (n=775) | Hemostasis Lab |
| Alpha2-AP [4] | CRS (n=936) | Visit 2 | Incident Stroke , Visit 2-31 December 98 (n=248) | Hemostasis Lab |

Analytes for Case Control Studies

| Analyte Names | CRS/Control Group | CRS Source | Case Group and/or Source | Blood Source |
|-----------------------|---|----------------|--|--|
| ALT | | Visit 1, 2 & 4 | | control samples came from the Minnesota inventory and the serum for the cases came from Baylor inventory |
| Amyloid A protein [2] | | | Withdrawn from 3-group, CRS, African-American, MRI, PAD (SC08/05/96) | Hemostasis Lab |
| Anti-GAD [3] | Diabetes CRS (n=681) | Visit 1 | Incident Diabetes, Visit1-Visit4 (n=581) | Lipid Lab |
| aPC resistance [2] | Table 2 Large or Small? Not in the dictionary | | CRS 2-group approved 06/05/96 | Hemostasis Lab |
| aPC resistance [2] | | | Withdrawn from Thin 2-Group | Hemostasis Lab |
| ApoA-I [2] | Table 2 Large | Visit 1 | Incident CHD, Visit 1-31Dec93 (n=471) | Lipid Lab |
| ApoA-I [2] | Table 2 Large | Visit 1 | Prevalent PAD, Visit 1 (n=237) | Lipid Lab |
| ApoA-I [2] | | | 3-group, African-American | Lipid Lab |
| ApoA-I [2] | | | MRI | Lipid Lab |
| ApoC-III [2] | Table 2 Large | Visit 1 | Incident CHD, Visit 1-31Dec93 (n=471) | Lipid Lab |
| ApoC-III [2] | | | 3-group | Lipid Lab |
| ApoC-III [2] | | | Withdrawn from PAD, Visit 1 (n=237) | Lipid Lab |
| B(12) vitamin [2] | Table 2 Small | Visit 1 | Incident CHD, Visit 1-31Dec91 (n= 267) | Chemistry Lab |
| B(6) vitamin [2] | Table 2 Small | Visit 1 | Incident CHD, Visit 1-31Dec91 (n= 267) | Chemistry Lab |
| Beta TG [4] | CRS (n=936) | Visit 2 | Incident CHD , Visit 2-31 December 98 (n=775) | Hemostasis Lab |
| Beta TG [4] | CRS (n=936) | Visit 2 | Incident Stroke , Visit 2-31 December 98 (n=248) | Hemostasis Lab |
| B-thromboglobulin [2] | Table 2 Large | Visit 1 | Incident CHD, Visit 1-31Dec93 (n=471) | Hemostasis Lab |
| B-thromboglobulin [2] | Table 2 Large | Visit 1 | Prevalent PAD, Visit 1 (n=237) | Hemostasis Lab |

Analytes for Case Control Studies

| Analyte Names | CRS/Control Group | CRS Source | Case Group and/or Source | Blood Source |
|--------------------------------------|---|---|--|--|
| B-thromboglobulin [2] | | | 3-Group | Hemostasis Lab |
| B-thromboglobulin [2] | | | African-American | Hemostasis Lab |
| B-thromboglobulin [2] | | | MRI | Hemostasis Lab |
| B-thromboglobulin [2] | | | CHD Incident Supplement | Hemostasis Lab |
| CD40 Ligand [4] | CRS (n=936) | Visit 2 | Incident CHD , Visit 2-31 December 98 (n=775) | Lipid Lab |
| CD40 Ligand [4] | CRS (n=936) | Visit 2 | Incident Stroke , Visit 2-31 December 98 (n=248) | Lipid Lab |
| CETP [2] | Table 2 Large | Visit 1 | Incident CHD, Visit 1-31Dec93 (n=471) | Lipid Lab |
| CETP [2] | Table 2 Large | Visit 1 | Prevalent PAD, Visit 1 (n=237) | Lipid Lab |
| CETP [2] | | | 3-Group | Lipid Lab |
| CETP [2] | | | African-American | Lipid Lab |
| CETP [2] | | | MRI | Lipid Lab |
| CETP [2] | | | CHD Incident Supplement | Lipid Lab |
| CETP activity | Visit3: CRS (N=148); Visit4:CRS (N=234) | Visit3/Visit4 | PADv3 (N=148)/PADv4 (N=234) | Lipid Lab |
| Chlamydia pneumoniae antibody [2] | Table 2 Small | Visit 1 | Incident CHD, Visit 1-31Dec91 (n= 267) | Chemistry Lab |
| Chlamydia pneumoniae antibody [2] | | | MRI | Chemistry Lab |
| CMV [2] | Table 2 Small | Visit 1 | Incident CHD, Visit 1-31Dec91 (n= 267) | Chemistry Lab |
| CMV [2] | | | MRI | Chemistry Lab |
| C-reactive protein [2] | Table 2 Large | Visit 1 | Incident CHD, Visit 1-31Dec93 (n=471) | Hemostasis Lab |
| C-reactive protein [2] | Table 2 Large | Visit 1 | Prevalent PAD, Visit 1 (n=237) | Hemostasis Lab |
| C-reactive protein [2] | | | 3-Group | Hemostasis Lab |
| C-reactive protein [2] | | | African-American | Hemostasis Lab |
| C-reactive protein [2] | | | MRI | Hemostasis Lab |
| C-reactive protein [2] | | | CHD Incident Supplement | Hemostasis Lab |
| Creatinine | N/A (all visit 4 participants with specimen) | N/A (all visit 4 participants with specimen) | N/A (all visit 4 participants with specimen) | Urine source -- University of Minnesota |
| CRP [3] | CRS (n=486) | Visit 2 | Incident CHD, Visit2-31Dec95 (n=406) | Hemostasis Lab |

Analytes for Case Control Studies

| Analyte Names | CRS/Control Group | CRS Source | Case Group and/or Source | Blood Source |
|--|--|--|--|--|
| CRP [3] | MRI CRS (n=267) | Visit 3 | MRI, Visit 3 (n=237) | Hemostasis Lab |
| CRP [3] | Periodontal Disease CRS (n=200) | Visit 4 | Periodontal, Visit4 (n=207) | Hemostasis Lab |
| CRP [4] | CRS (n=936) | Visit 2 | Incident CHD , Visit 2-31 December 98 (n=775) | Lipid Lab |
| CRP [4] | CRS (n=936) | Visit 2 | Incident Stroke , Visit 2-31 December 98 (n=248) | Lipid Lab |
| CRP [5] | Visit3: CRS (N=148); Visit4:CRS (N=148) | Visit3/Visit4 | PADv3 (N=148)/PADv4 (N=234) | Lipid Lab |
| Cystatin C | N/A (measured on the entire visit 4 cohort (with a few exceptions for ethnicity other than white or black) | N/A (measured on the entire visit 4 cohort (with a few exceptions for ethnicity other than white or black) | N/A (measured on the entire visit 4 cohort (with a few exceptions for ethnicity other than white or black) | Lipid lab (EDTA plasma from visit 4) |
| D-Dimer [2] | Table 2 Large | Visit 1 | Incident CHD, Visit 1-31Dec93 (n=471) | Hemostasis Lab |
| D-Dimer [2] | Table 2 Large | Visit 1 | Prevalent PAD, Visit 1 (n=237) | Hemostasis Lab |
| D-Dimer [2] | | | 3-Group | Hemostasis Lab |
| D-Dimer [2] | | | African-American | Hemostasis Lab |
| D-Dimer [2] | | | MRI | Hemostasis Lab |
| D-Dimer [2] | | | CHD Incident Supplement | Hemostasis Lab |
| D-Dimer [3] | MRI CRS (n=267) | Visit 3 | MRI, Visit 3 (n=237) | Hemostasis Lab |
| D-Dimer [3] | Periodontal Disease CRS | Visit 4 | Periodontal, Visit4 (n=207) | Hemostasis Lab |
| D-Dimer [4] | CRS (n=936) | Visit 2 | Incident CHD , Visit 2-31 December 98 (n=775) | Hemostasis Lab |
| D-Dimer [4] | CRS (n=936) | Visit 2 | Incident Stroke , Visit 2-31 December 98 (n=248) | Hemostasis Lab |
| DPP-IV | a case cohort study of incident diabetes that includes a random sample of incident diabetes cases (n=581) and a random sample of the cohort (n=693). | Visit 1 | a case cohort study of incident diabetes that includes a random sample of incident diabetes cases (n=581) and a random sample of the cohort (n=693). | ARIC Visit 1 EDTA plasma samples stored at the lipid lab |
| Endothel TM (Endothelial Thrombomodulin) [3] | MRI CRS (n=267) | Visit 3 | MRI, Visit 3 (n=237) | Hemostasis Lab |

Analytes for Case Control Studies

| Analyte Names | CRS/Control Group | CRS Source | Case Group and/or Source | Blood Source |
|---|--|--------------------------|--|-----------------------------|
| Endothel TM (Endothelial Thrombomodulin) [3] Eotaxin | Periodontal Disease CRS (n=200) Visit3:CRS (N=148); Visit4: CRS (N=234) | Visit 4 Visit3/Visit4 | Periodontal, Visit4 (n=207) PADv3 (N=148)/PADv4 (N=234) | Hemostasis Lab Lipid Lab |
| E-selectin [2] | Table 2 Large | Visit 1 | Incident CHD, Visit 1-31Dec93 (n=471) | Lipid Lab |
| E-selectin [2] | Table 2 Large | Visit 1 | Prevalent PAD, Visit 1 (n=237) | Lipid Lab |
| E-selectin [2] | | | 3-group | Lipid Lab |
| E-selectin [2] | | | MRI | Lipid Lab |
| E-selectin [2] | | | African-American | Lipid Lab |
| E-selectin [3] | | | | Lipid Lab |
| F1.2 [2] | Table 2 Large | Visit 1 | Incident CHD, Visit 1-31Dec93 (n=471) | Hemostasis Lab |
| F1.2 [2] | Table 2 Large | Visit 1 | Prevalent PAD, Visit 1 (n=237) | Hemostasis Lab |
| F1.2 [2] | | | Withdrawn from 3-Group, CRS, African-American, CHD Incident Supplement | Hemostasis Lab |
| F1.2 [2] | | | MRI | Hemostasis Lab |
| Factor II (prothrombin) [4] | CRS (n=936) | Visit 2 | Incident CHD , Visit 2-31 December 98 (n=775) | Hemostasis Lab |
| Factor II (prothrombin) [4] | CRS (n=936) | Visit 2 | Incident Stroke , Visit 2-31 December 98 (n=248) | Hemostasis Lab |
| Factor IX [4] | CRS (n=936) | Visit 2 | Incident CHD , Visit 2-31 December 98 (n=775) | Hemostasis Lab |
| Factor IX [4] | CRS (n=936) | Visit 2 | Incident Stroke , Visit 2-31 December 98 (n=248) | Hemostasis Lab |
| Factor V [4] | CRS (n=936) | Visit 2 | Incident CHD , Visit 2-31 December 98 (n=775) | Hemostasis Lab |
| Factor V [4] | CRS (n=936) | Visit 2 | Incident Stroke , Visit 2-31 December 98 (n=248) | Hemostasis Lab |
| Factor V Leiden [2] | Table 2 Small | Visit 1 | Incident CHD, Visit 1-31Dec93 (n=471) | Hemostasis Lab |

Analytes for Case Control Studies

| Analyte Names | CRS/Control Group | CRS Source | Case Group and/or Source | Blood Source |
|--|---|----------------|---|---|
| Factor V Leiden [2] | | | CHD Incident Supplement | Hemostasis Lab |
| Factor V Leiden [2] | | | Withdrawn from Thin 2-Group | Hemostasis Lab |
| Factor VIIa [2] | | | Withdrawn from Thin 2-Group | Hemostasis Lab |
| Factor VIIag [2] | | | Withdrawn from Thin 2-Group | Hemostasis Lab |
| Factor X [4] | CRS (n=936) | Visit 2 | Incident CHD , Visit 2-31 December 98 (n=775) | Hemostasis Lab |
| Factor X [4] | CRS (n=936) | Visit 2 | Incident Stroke , Visit 2-31 December 98 (n=248) | Hemostasis Lab |
| Factor XI [4] | CRS (n=936) | Visit 2 | Incident CHD , Visit 2-31 December 98 (n=775) | Hemostasis Lab |
| Factor XI [4] | CRS (n=936) | Visit 2 | Incident Stroke , Visit 2-31 December 98 (n=248) | Hemostasis Lab |
| Factor XII [4] | CRS (n=936) | Visit 2 | Incident CHD , Visit 2-31 December 98 (n=775) | Hemostasis Lab |
| Factor XII [4] | CRS (n=936) | Visit 2 | Incident Stroke , Visit 2-31 December 98 (n=248) | Hemostasis Lab |
| Factor XIIa [2] Ferritin | | Visit 1, 2 & 4 | Withdrawn from Thin 2-group | Hemostasis Lab control samples came from the Minnesota inventory and the serum for the cases came from Baylor inventory |
| Fetuin-A | a case cohort study of incident diabetes that includes a random sample of incident diabetes cases (n=581) and a random sample of the cohort (n=693). | Visit 1 | a case cohort study of incident diabetes that includes a random sample of incident diabetes cases (n=581) and a random sample of the cohort (n=693). | ARIC Visit 1 EDTA plasma samples stored at the lipid lab |
| Fibrinogen (Completed at Visit 1) [2] | | | Withdrawn from 3-group, CRS Table2 Large, African- American, MRI, PAD | Hemostasis Lab |
| Fibrinogen [3] | CRS (n=486) | Visit 2 | Incident CHD, Visit2-31Dec95 (n=406) | Hemostasis Lab |

Analytes for Case Control Studies

| Analyte Names | CRS/Control Group | CRS Source | Case Group and/or Source | Blood Source |
|----------------------------------|--|--|--|--|
| Fibrinogen [3] | MRI CRS (n=267) | Visit 3 | MRI, Visit 3 (n=237) | Hemostasis Lab |
| Fibrinogen [3] | Periodontal Disease CRS (n=200) | Visit 4 | Periodontal, Visit4 (n=207) | Hemostasis Lab |
| Folate [2] | Table 2 Small | Visit 1 | Incident CHD, Visit 1-31Dec91 (n= 267) | Chemistry Lab |
| Gamma fibrinogen [4] | | | | Hemostasis Lab |
| GC-1 | Visit3: CRS (N=148); Visit4: CRS (N=234) | Visit3/Visit4 | PADv3 (N=148)/PADv4 (N=234) | Lipid Lab |
| GGT | | Visit 1/Visit 2/Visit 4 | | control samples came from the Minnesota inventory and the serum for the cases came from Baylor inventory |
| hba1c | Table 4 cohort random sample and all persons with diabetes at any visit by definition | Visit 2 and ect | Table 4 case-cohort, all CHD cases, all stroke cases, and all CKD cases to 2001 | whole blood samples from Visit 2 stored at the University of Minnesota |
| Helicobacter Pylori antibody [2] | Table 2 Small | Visit 1 | Incident CHD, Visit 1-31Dec91 (n= 267) | Chemistry Lab |
| Helicobacter Pylori antibody [2] | | | MRI | Chemistry Lab |
| Heparin Co-F2 [4] | CRS (n=936) | Visit 2 | Incident CHD , Visit 2-31 December 98 (n=775) | Hemostasis Lab |
| Heparin Co-F2 [4] | CRS (n=936) | Visit 2 | Incident Stroke , Visit 2-31 December 98 (n=248) | Hemostasis Lab |
| Herpes Simplex I antibody [2] | Table 2 Small | Visit 1 | Incident CHD, Visit 1-31Dec91 (n= 267) | Chemistry Lab |
| Herpes Simplex I antibody [2] | | | MRI | Chemistry Lab |
| Homocysteine [2] | Table 2 Small | Visit 1 | Incident CHD, Visit 1-31Dec91 (n= 267) | Chemistry Lab |
| Homocysteine [2] | | | MRI | Chemistry Lab |
| HsCRP | N/A (measured on the entire visit 4 cohort (with a few exceptions for ethnicity other than white or black) | N/A (measured on the entire visit 4 cohort (with a few exceptions for ethnicity other than white or black) | N/A (measured on the entire visit 4 cohort (with a few exceptions for ethnicity other than white or black) | Lipid lab (EDTA plasma from visit 4) |

Analytes for Case Control Studies

| Analyte Names | CRS/Control Group | CRS Source | Case Group and/or Source | Blood Source |
|-------------------|--|-------------------------|--|--|
| Hyaluronic Acid | | Visit 1/Visit 2/Visit 4 | | control samples came from the Minnesota inventory and the serum for the cases came from Baylor inventory |
| ICAM-1 [2] | Table 2 Large | Visit 1 | Incident CHD, Visit 1-31Dec93 (n=471) | Lipid Lab |
| ICAM-1 [2] | Table 2 Large | Visit 1 | Prevalent PAD, Visit 1 (n=237) | Lipid Lab |
| ICAM-1 [2] | | | 3-group | Lipid Lab |
| ICAM-1 [2] | | | African-American | Lipid Lab |
| ICAM-1 [2] | | | MRI | Lipid Lab |
| ICAM-1 [4] | CRS (n=936) | Visit 2 | Incident CHD , Visit 2-31 December 98 (n=775) | Lipid Lab |
| ICAM-1 [4] | CRS (n=936) | Visit 2 | Incident Stroke , Visit 2-31 | Lipid Lab |
| ICAM-1[3] | | | | Lipid Lab |
| IL-18 | a case cohort study of incident diabetes that includes a random sample of incident diabetes cases (n=581) and a random sample of the cohort (n=693). | Visit 1 | a case cohort study of incident diabetes that includes a random sample of incident diabetes cases (n=581) and a random sample of the cohort (n=693). | ARIC Visit 1 EDTA plasma samples stored at the lipid lab |
| IL-6 receptor [3] | | | Withdrawn from MRI CRS, Periodontal Disease CRS, V2CHD | Lipid Lab |
| Interleukin-6 [3] | Diabetes CRS (n=681) | Visit 1 | Incident Diabetes, Visit1-Visit4 (n=581) | Lipid Lab |
| Interleukin-6 [3] | CRS (n=486) | Visit 2 | Incident CHD, Visit2-31Dec95 (n=406) | Lipid Lab |
| Iron | | Visit 1, 2 & 4 | | control samples came from the Minnesota inventory and the serum for the cases came from Baylor inventory |

Analytes for Case Control Studies

| Analyte Names | CRS/Control Group | CRS Source | Case Group and/or Source | Blood Source |
|----------------------------------|--|---------------|--|--|
| Lactate | a case cohort study of incident diabetes that includes a random sample of incident diabetes cases (n=581) and a random sample of the cohort (n=693). | Visit 1 | a case cohort study of incident diabetes that includes a random sample of incident diabetes cases (n=581) and a random sample of the cohort (n=693). | ARIC Visit 1 EDTA plasma samples stored at the lipid lab |
| LDL size (3-Group Completed) [2] | | | Withdrawn from 3-group (MS# 96), CRS table 2 large, PAD | Lipid Lab |
| Leptin [2] | Table 2 Large | Visit 1 | Incident CHD, Visit 1-31Dec93 (n=471) | Lipid Lab |
| Leptin [2] | Table 2 Large | Visit 1 | Prevalent PAD, Visit 1 (n=237) | Lipid Lab |
| Leptin [2] | | | 3-Group | Lipid Lab |
| Leptin [2] | | | African-American | Lipid Lab |
| Leptin [2] | | | MRI | Lipid Lab |
| Leptin [2] | | | CHD Incident Supplement | Lipid Lab |
| Lp(a) Isoforms[2] | Table 2 Large | Visit 1 | Incident CHD, Visit 1-31Dec93 (n=471) | Lipid Lab |
| Lp(a) Isoforms[2] | Table 2 Large | Visit 1 | Prevalent PAD, Visit 1 (n=237) | Lipid Lab |
| Lp(a) Isoforms[2] | | | Withdrawn from 3-Group, | Lipid Lab |
| LpA-1 [2] | | | Withdrawn from 3-Group, CRS | Lipid Lab |
| LpA-I/A-II [2] | | | Withdrawn from 3-Group, CRS table 2 large, PAD | Lipid Lab |
| LpPLA2 [4] | CRS (n=936) | Visit 2 | Incident CHD , Visit 2-31 December 98 (n=775) | Lipid Lab |
| LpPLA2 [4] | CRS (n=936) | Visit 2 | Incident Stroke , Visit 2-31 December 98 (n=248) | Lipid Lab |
| LpPLA2 activity | Visit3: CRS (N=148); Visit4: | Visit3/Visit4 | PADv3 (N=148)/PADv4 | Lipid Lab |
| LpPLA2 mass | Visit3: CRS (N=148); Visit4: | Visit3/Visit4 | PADv3 (N=148)/PADv4 | Lipid Lab |
| L-selectin [2] | Table 2 Large | Visit 1 | Incident CHD, Visit 1-31Dec93 (n=471) | Lipid Lab |
| L-selectin [2] | Table 2 Large | Visit 1 | Prevalent PAD, Visit 1 (n=237) | Lipid Lab |
| L-selectin [2] | | | 3-group | Lipid Lab |

Analytes for Case Control Studies

| Analyte Names | CRS/Control Group | CRS Source | Case Group and/or Source | Blood Source |
|---|--|---------------|---|---|
| L-selectin [2] | | | African-American | Lipid Lab |
| L-selectin [2] | | | MRI | Lipid Lab |
| L-selectin [3] | | | W | Lipid Lab |
| L-Selectin [3] | | | Withdrawn from MRI | Lipid Lab |
| Luninex panel [4] | | | Withdrawn from CHDV2 CRS (n=936); Stroke V2 (n=936) | Lipid Lab |
| Mean Factor H | Visit3: CRS (N=148)/Visit4:CRS (N=234) | Visit3/Visit4 | Visit3: CRS (N=148)/Visit4:CRS (N=234) | Central Lipid Lab., visits 3 & 4 tubes =Tube # 6 EDTA plasma (lavender top) |
| MMP-1[3] | CRS (n=486) | Visit 2 | Incident CHD, Visit2-31Dec95 (n=406) | Lipid Lab |
| Monocyte Chemo-attractant Protein-1 (MCP-1) [2] | Table 2 Large | Visit 1 | Incident CHD, Visit 1-31Dec93 (n=471) | Lipid Lab |
| Monocyte Chemo-attractant Protein-1 (MCP-1) [2] | Table 2 Large | Visit 1 | Prevalent PAD, Visit 1 (n=237) | Lipid Lab |
| Monocyte Chemo-attractant Protein-1 (MCP-1) [2] | | | 3-Group | Lipid Lab |
| Monocyte Chemo-attractant Protein-1 (MCP-1) [2] | | | African-American | Lipid Lab |
| Monocyte Chemo-attractant Protein-1 (MCP-1) [2] | | | MRI | Lipid Lab |
| Monocyte Chemo-attractant Protein-1 (MCP-1) [2] | | | CHD Incident Supplement | Lipid Lab |
| MPO | Visit3: CRS (N=148); Visit4: CRS (N=234) | Visit3/Visit4 | PADv3 (N=148)/PADv4 (N=234) | Lipid Lab |
| Ox-LDL | Visit3: CRS (N=148); Visit4: CRS (N=234) | Visit3/Visit4 | PADv3 (N=148)/PADv4 (N=234) | Lipid Lab |
| PAI-1 | MRI CRS (n=267) | Visit 3 | MRI, Visit 3 (n=237) | Hemostasis Lab |
| PAI-1 | Periodontal Disease CRS (n=200) | Visit 4 | Periodontal, Visit4 (n=207) | Hemostasis Lab |
| PAI-I [2] | Table 2 Large | Visit 1 | Incident CHD, Visit 1-31Dec93 (n=471) | Hemostasis Lab |
| PAI-I [2] | Table 2 Large | Visit 1 | Prevalent PAD, Visit 1 (n=237) | Hemostasis Lab |
| PAI-I [2] | | | 3-Group | Hemostasis Lab |
| PAI-I [2] | | | African-American | Hemostasis Lab |

Analytes for Case Control Studies

| Analyte Names | CRS/Control Group | CRS Source | Case Group and/or Source | Blood Source |
|------------------------|--|---------------|---|----------------|
| PAI-I [2] | | | MRI | Hemostasis Lab |
| PAI-I [2] | | | CHD Incident Supplement | Hemostasis Lab |
| Plasma fatty acids [2] | Table 2 Small | Visit 1 | Incident CHD, Visit 1-31Dec91 (n= 267) | Chemistry Lab |
| Plasminogen [2] | Table 2 Large | Visit 1 | Incident CHD, Visit 1-31Dec93 (n=471) | Hemostasis Lab |
| Plasminogen [2] | Table 2 Large | Visit 1 | Prevalent PAD, Visit 1 (n=237) | Hemostasis Lab |
| Plasminogen [2] | | | 3-group | Hemostasis Lab |
| Plasminogen [2] | | | African-American | Hemostasis Lab |
| Plasminogen [2] | | | MRI | Hemostasis Lab |
| Plasminogen [2] | | | CHD Incident Supplement | Hemostasis Lab |
| Plasminogen [3] | MRI CRS (n=267) | Visit 3 | MRI, Visit 3 (n=237) | Hemostasis Lab |
| Plasminogen [3] | Periodontal Disease CRS (n=200) | Visit 4 | Periodontal, Visit4 (n=207) | Hemostasis Lab |
| Plasminogen [4] | CRS (n=936) | Visit 2 | Incident CHD , Visit 2-31 December 98 (n=775) | Hemostasis Lab |
| Plasminogen [4] | CRS (n=936) | Visit 2 | Incident Stroke , Visit 2-31 December 98 (n=248) | Hemostasis Lab |
| Platelet β TG | MRI CRS (n=267) | Visit 3 | MRI, Visit 3 (n=237) | Hemostasis Lab |
| Protein Z [4] | CRS (n=936) | Visit 2 | Incident CHD , Visit 2-31 December 98 (n=775) | Hemostasis Lab |
| Protein Z [4] | CRS (n=936) | Visit 2 | Incident Stroke , Visit 2-31 December 98 (n=248) | Hemostasis Lab |
| Protein ZPI [4] | CRS (n=936) | Visit 2 | Incident CHD , Visit 2-31 December 98 (n=775) | Hemostasis Lab |
| Protein ZPI [4] | CRS (n=936) | Visit 2 | Incident Stroke , Visit 2-31 December 98 (n=248) | Hemostasis Lab |
| P-selectin [2] | Table 2 Large | Visit 1 | Incident CHD, Visit 1-31Dec93 (n=471) | Lipid Lab |
| P-selectin [2] | | | PAD | Lipid Lab |
| P-selectin [2] | | | 3-group | Lipid Lab |
| P-selectin [2] | | | MRI | Lipid Lab |
| P-selectin [2] | | | African-American | Lipid Lab |
| P-selectin [3] | | | | Lipid Lab |
| RANTES | Visit3: CRS (N=148); Visit4: CRS (N=234) | Visit3/Visit4 | PADv3 (N=148)/PADv4 (N=234) | Lipid Lab |

Analytes for Case Control Studies

| Analyte Names | CRS/Control Group | CRS Source | Case Group and/or Source | Blood Source |
|-------------------------------------|--|----------------|--|--|
| RBP-4 | a case cohort study of incident diabetes that includes a random sample of incident diabetes cases (n=581) and a random sample of the cohort (n=693). | Visit 1 | a case cohort study of incident diabetes that includes a random sample of incident diabetes cases (n=581) and a random sample of the cohort (n=693). | ARIC Visit 1 EDTA plasma samples stored at the lipid lab |
| Remnant Lipoprotein-cholesterol [4] | | | Withdrawn from CHDV2 CRS (n=936); Stroke V2 (n=936) | Lipid Lab |
| SDF-1a | Visit3: CRS (N=148); Visit4: CRS (N=234) | Visit3/Visit4 | PADv3 (N=148)/PADv4 (N=234) | Lipid Lab |
| Soluble thrombomodulin [2] | Table 2 Large | Visit 1 | Incident CHD, Visit 1-31Dec93 (n=471) | Hemostasis Lab |
| Soluble thrombomodulin [2] | Table 2 Large | Visit 1 | Prevalent PAD, Visit 1 (n=237) | Hemostasis Lab |
| Soluble thrombomodulin [2] | | | 3-group | Hemostasis Lab |
| Soluble thrombomodulin [2] | | | African-American | Hemostasis Lab |
| Soluble thrombomodulin [2] | | | MRI | Hemostasis Lab |
| Soluble Thrombomodulin [4] | CRS (n=936) | Visit 2 | Incident Stroke, Visit 2-31 December 98 (n=248) | Hemostasis Lab |
| Soluble Thrombomodulin [4] | CRS (n=936) | Visit 2 | Incident CHD, Visit 2-31 December 98 (n=775) | Hemostasis Lab |
| TGF- β receptor [3] | | | Withdrawn from V2CHD CRS (n=486) | Lipid Lab |
| TIBC | | Visit 1, 2 & 4 | | control samples came from the Minnesota inventory and the serum for the cases came from Baylor inventory |
| TIMP-1 [3] | CRS (n=486) | Visit 2 | Incident CHD, Visit2-31Dec95 (n=406) | Lipid Lab |
| TNF- α receptor [3] | Diabetes CRS (n=681) | Visit 1 | Incident Diabetes, Visit1-Visit4 (n=581) | Lipid Lab |
| TNF- α receptor [3] | | | Withdrawn from periodontal disease CRS (n=200), V2CHD CRS (n=486) | Lipid Lab |

Analytes for Case Control Studies

| Analyte Names | CRS/Control Group | CRS Source | Case Group and/or Source | Blood Source |
|--|--------------------------------|-------------------------|--|--|
| Total Bilirubin | | Visit 1/Visit 2/Visit 4 | | control samples came from the Minnesota inventory and the serum for the cases came from Baylor inventory |
| Tpa [2] | Table 2 Large | Visit 1 | Incident CHD, Visit 1-31Dec93 (n=471) | Hemostasis Lab |
| Tpa [2] | Table 2 Large | Visit 1 | Prevalent PAD, Visit 1 (n=237) | Hemostasis Lab |
| Tpa [2] | | | 3-Group | Hemostasis Lab |
| Tpa [2] | | | African-American | Hemostasis Lab |
| Tpa [2] | | | MRI | Hemostasis Lab |
| Tpa [2] | | | CHD Incident Supplement | Hemostasis Lab |
| tPA [3] | MRI CRS (n=267) | Visit 3 | MRI, Visit 3 (n=237) | Hemostasis Lab |
| tPA [3] | Periodontal Disease CRS (n=20) | Visit 4 | Periodontal, Visit4 (n=207) | Hemostasis Lab |
| Transferrin Saturation | | Visit 1, 2 & 4 | | control samples came from the Minnesota inventory and the serum for the cases came from Baylor inventory |
| Transforming Growth factor α (TGF- α receptor) [2] | | | Withdrawn from 3-Group, CRS table 2 large, African-American, MRI, PAD, CHD Incident Supplement | Lipid Lab |
| Transforming Growth factor β [3] | | | Withdrawn from V2CHD CRS (n=486) | Lipid Lab |
| Tumor Necrosis Factor- α [3] | | | | Lipid Lab |
| UIBC | | Visit 1, 2 & 4 | | control samples came from the Minnesota inventory and the serum for the cases came from Baylor inventory |
| VCAM-1 [2] | Table 2 Large | Visit 1 | Incident CHD, Visit 1-31Dec93 (n=471) | Lipid Lab |
| VCAM-1 [2] | Table 2 Large | Visit 1 | Prevalent PAD, Visit 1 (n=237) | Lipid Lab |
| VCAM-1 [2] | | | 3-Group | Lipid Lab |
| VCAM-1 [2] | | | MRI | Lipid Lab |
| VCAM-1 [2] | | | African-American | Lipid Lab |
| Von Willebrand Factor[3] | CRS (n=486) | Visit 2 | Incident CHD, Visit2-31Dec95 (n=406) | Hemostasis Lab |

Analytes for Case Control Studies

| Analyte Names | CRS/Control Group | CRS Source | Case Group and/or Source | Blood Source |
|--------------------------|------------------------------------|-------------------|---------------------------------|---------------------|
| Von Willebrand Factor[3] | MRI CRS (n=267) | Visit 3 | MRI, Visit 3 (n=237) | Hemostasis Lab |
| Von Willebrand Factor[3] | Periodontal Disease CRS (n=200) | Visit 4 | Periodontal, Visit4 (n=207) | Hemostasis Lab |

| Full Name of Gene | Gene Abbreviation | Alias | dbSNP ID | SNP_ID | ARIC Sample Set | Principal Investigator or of Ancillary Study | Replicate Pair QC Result | | |
|--|-------------------|--------------------------|------------|-----------------|---------------------|---|--|--|--|
| | | | | | | | QC Matched Number (*Information not available for some old data) | % of Agreements | Simple Kappa Coefficient |
| Adducin 1 (alpha) | ADD1 | Gly460Trp | rs4961 | ADD1A__460 | entire cohort | Boerwinkle (contract) / (GxE) | 738 | 97.43 | 0.94 |
| Adrenergic Receptor Beta 2 | ADRB2 | Arg16Gly | rs1042713 | ARB2A__16 | entire cohort | Boerwinkle (GxE) | 750 | 95.73 | 0.93 |
| Adrenergic Receptor Beta 2 | ADRB2 | Gln27Glu | rs1042714 | ARB2A__27 | entire cohort | Boerwinkle (GxE) | 718 | 96.52 | 0.94 |
| Adrenergic Receptor Beta 3 | ADRB3 | Trp64Arg | rs4994 | ARB3A__64 | entire cohort | Boerwinkle (contract) / (GxE) | 749 | 98.26 | 0.94 |
| Angiotensin Converting Enzyme | ACE | I/D 287 bp intron 16 | NA | ACE__1622 | Tables 2 and 3 | Boerwinkle (contract) / Boerwinkle | see Replicate Pair Analysis for Tables 2, 3, & 4 | see Replicate Pair Analysis for Tables 2, 3, & 5 | see Replicate Pair Analysis for Tables 2, 3, & 6 |
| angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 | ACE | hCV11942637 | rs4364 | C__11942637_10 | entire cohort | Boerwinkle (GxE) | 725 | 99.31 | 0.92 |
| Angiotensin II Type 1 Receptor | AGTR1 | A1166C 3' untranslated | rs5186 | AT1RN_1166 | entire cohort | Boerwinkle (contract) / (GxE) | 774 | 94.83 | 0.91 |
| Angiotensinogen | AGT | Met235Thr | rs699 | AGT_A__235 | Table 2 | Boerwinkle (contract) / Boerwinkle | see Replicate Pair Analysis for Tables 2, 3, & 4 | see Replicate Pair Analysis for Tables 2, 3, & 5 | see Replicate Pair Analysis for Tables 2, 3, & 6 |
| Angiotensinogen | AGT | -6 | rs5051 | AGT_N__M6 | Tables 2 and 3 | Boerwinkle (contract) | 724 | 94.61 | 0.92 |
| Apolipoprotein B | APOB | I/D 9 bp (SPB-29,27,24) | NA | APOBI__152 | Table 2 | Boerwinkle (contract) / Neil | see Replicate Pair Analysis for Tables 2, 3, & 4 | see Replicate Pair Analysis for Tables 2, 3, & 5 | see Replicate Pair Analysis for Tables 2, 3, & 6 |
| apolipoprotein C-I | APOC1 | | rs12721054 | C__25767178_20 | entire cohort | Schacter Neil | 750 | 99.6 | 0.95 |
| apolipoprotein C-I | APOC1 | | rs11568822 | APOC1_RS11-5688 | entire cohort | Schacter Boerwinkle (contract) / | 746 | 96.25 | 0.93 |
| Apolipoprotein E | APOE | Cys112Arg | rs429358 | APOEA__112 | entire cohort | Boerwinkle (contract) / | | 97.24 | 0.94 |
| Apolipoprotein E | APOE | Cys158Arg | rs7412 | APOEA__158 | entire cohort | Boerwinkle (contract) / Boerwinkle (contract) / | | 98.29 | 0.94 |
| Cholesteryl Ester Transfer Protein | CETP | G>A, TaqI restrict. Site | rs708272 | CETPR_TAQI | entire cohort | Boerwinkle (contract) / (GxE) | 727 | 95.46 | 0.93 |
| Collagen Type I Receptor | CD36 | I/D 15 bp | NA | CD36I__433 | Table 3 | Boerwinkle (contract) | see Replicate Pair Analysis for Tables 2, 3, & 4 | see Replicate Pair Analysis for Tables 2, 3, & 5 | see Replicate Pair Analysis for Tables 2, 3, & 6 |
| C-reactive protein, pentraxin-related | CRP | | rs2794521 | CRP_rs2794521 | Table 4 | Boerwinkle (contract) / Boerwinkle | see Replicate Pair Analysis for Tables 2, 3, & 4 | see Replicate Pair Analysis for Tables 2, 3, & 5 | see Replicate Pair Analysis for Tables 2, 3, & 6 |
| cytochrome b-245, alpha polypeptide | CYBA | | rs4673 | C__2038_20 | entire cohort | Boerwinkle (GxE) | 728 | 96.02 | 0.93 |
| endothelin receptor type A | EDNRA | | rs5343 | C__1736664_10 | entire cohort | Boerwinkle (GxE) | 755 | 96.03 | 0.93 |
| endothelin receptor type A | EDNRA | | rs5334 | C__1736669_1_ | entire cohort | Boerwinkle (GxE) | 728 | 95.74 | 0.93 |
| endothelin receptor type A | EDNRA | | rs5333 | C__1736670_1_ | entire cohort | Boerwinkle (GxE) | 736 | 96.2 | 0.93 |
| epoxide hydrolase 2, cytoplasmic | EPHX2 | | rs17057255 | EPHX2_A103C | Table 4 individuals | Myriam Fornage | 161 | 100 | 1 |
| epoxide hydrolase 2, cytoplasmic | EPHX2 | | rs11996801 | EPHX2_G197G | Table 4 individuals | Myriam Fornage | 156 | 99.36 | 0.95 |
| epoxide hydrolase 2, cytoplasmic | EPHX2 | | NA | EPHX2_L55A | Table 4 individuals | Myriam Fornage | 163 | 96.32 | 0.9 |
| epoxide hydrolase 2, cytoplasmic | EPHX2 | | NA | EPHX2_N32445 | Table 4 individuals | Myriam Fornage | 161 | 99.38 | 0.92 |
| epoxide hydrolase 2, cytoplasmic | EPHX2 | | NA | EPHX2_N46539 | Table 4 individuals | Myriam Fornage | 163 | 97.55 | 0.89 |
| epoxide hydrolase 2, cytoplasmic | EPHX2 | | rs4149259 | EPHX2_N54776 | Table 4 individuals | Myriam Fornage | 162 | 95.06 | 0.91 |
| epoxide hydrolase 2, cytoplasmic | EPHX2 | | rs1042032 | EPHX2_rs1042032 | Table 4 individuals | Myriam Fornage | 159 | 95.6 | 0.93 |